

**Study Number:** C12005-01  
**Test Type:** TOX  
**Route:** Oral Gavage  
**Species/Strain:** Rat/Harlan Sprague Dawley

**PA41: Clinical Chemistry Summary**  
**Test Compound:** Octrizole  
**CAS Number:** 3147-75-9

**Date Report Requested:** 04/08/2026  
**Time Report Requested:** 15:47:33  
**Lab:** Battelle

**Study Number:** C12005-01  
**Study Sex:** Male  
**PWG Approval Date:** See web page for date of PWG Approval  
**Version:** v1.7.4  
**Stat Version:** 2023.02.27S

Study Number: C12005-01

Test Type: TOX

Route: Oral Gavage

Species/Strain: Rat/Harlan Sprague Dawley

## PA41: Clinical Chemistry Summary

Test Compound: Octrizole

CAS Number: 3147-75-9

Date Report Requested: 04/08/2026

Time Report Requested: 15:47:33

Lab: Battelle

| Male                            |           |                          |                  |                  |                  |                  |
|---------------------------------|-----------|--------------------------|------------------|------------------|------------------|------------------|
|                                 | Phase Day | Treatment Groups (mg/kg) |                  |                  |                  |                  |
|                                 |           | 0                        | 30               | 100              | 300              | 1000             |
| Urea Nitrogen (mg/dL)           | SD 14     | 17.8 ± 0.4 (5)           | 20.6 ± 1.7 (5)   | 16.0 ± 0.3 (5)   | 19.4 ± 1.0 (5)   | 19.2 ± 0.6 (5)   |
| Percent of Control              |           |                          | 115.7            | 89.9             | 109.0            | 107.9            |
| Creatinine (mg/dL)              | SD 14     | 0.42 ± 0.02 (5)          | 0.46 ± 0.02 (5)  | 0.40 ± 0.00 (5)  | 0.42 ± 0.02 (5)  | 0.44 ± 0.02 (5)  |
| Percent of Control              |           |                          | 109.5            | 95.2             | 100.0            | 104.8            |
| Glucose (mg/dL)                 | SD 14     | 169.8 ± 10.5 (5)         | 238.8 ± 28.7 (5) | 153.0 ± 8.0 (5)  | 222.8 ± 13.4 (5) | 215.0 ± 19.2 (5) |
| Percent of Control              |           |                          | 140.6            | 90.1             | 131.2            | 126.6            |
| Total Protein (g/dL)            | SD 14     | 6.72 ± 0.07 (5)          | 6.74 ± 0.14 (5)  | 6.78 ± 0.10 (5)  | 6.70 ± 0.11 (5)  | 6.76 ± 0.09 (5)  |
| Percent of Control              |           |                          | 100.3            | 100.9            | 99.7             | 100.6            |
| Globulin (g/dL)                 | SD 14     | 2.32 ± 0.06 (5)          | 2.24 ± 0.10 (5)  | 2.66 ± 0.20 (5)  | 2.30 ± 0.09 (5)  | 2.30 ± 0.05 (5)  |
| Percent of Control              |           |                          | 96.6             | 114.7            | 99.1             | 99.1             |
| A/G Ratio                       | SD 14     | 1.90 ± 0.05 (5)          | 2.02 ± 0.08 (5)  | 1.60 ± 0.18 (5)  | 1.92 ± 0.07 (5)  | 1.94 ± 0.04 (5)  |
| Percent of Control              |           |                          | 106.4            | 84.1             | 101.2            | 102.2            |
| Albumin (g/dL)                  | SD 14     | 4.40 ± 0.04 (5)          | 4.50 ± 0.07 (5)  | 4.12 ± 0.20 (5)  | 4.40 ± 0.04 (5)  | 4.46 ± 0.05 (5)  |
| Percent of Control              |           |                          | 102.3            | 93.6             | 100.0            | 101.4            |
| Cholesterol (mg/dL)             | SD 14     | 115.2 ± 7.4 (5)          | 129.0 ± 7.1 (5)  | 107.8 ± 11.7 (5) | 116.2 ± 7.5 (5)  | 119.8 ± 6.9 (5)  |
| Percent of Control              |           |                          | 112.0            | 93.6             | 100.9            | 104.0            |
| Triglyceride (mg/dL)            | SD 14     | 97.0 ± 17.8 (5)          | 78.6 ± 5.6 (5)   | 98.4 ± 11.9 (5)  | 90.2 ± 31.5 (5)  | 106.0 ± 12.7 (5) |
| Percent of Control              |           |                          | 81.0             | 101.4            | 93.0             | 109.3            |
| Alanine Aminotransferase (IU/L) | SD 14     | 58.6 ± 3.7 (5)           | 65.2 ± 9.0 (5)   | 52.0 ± 3.5 (5)   | 53.8 ± 1.2 (5)   | 56.6 ± 4.2 (5)   |
| Percent of Control              |           |                          | 111.3            | 88.7             | 91.8             | 96.6             |
| Alkaline Phosphatase (IU/L)     | SD 14     | 214.6 ± 11.2 (5)         | 203.2 ± 8.1 (5)  | 201.2 ± 30.3 (5) | 207.2 ± 10.2 (5) | 219.0 ± 14.0 (5) |
| Percent of Control              |           |                          | 94.7             | 93.8             | 96.6             | 102.1            |

| Male                          |           |                          |                  |                   |                  |                  |
|-------------------------------|-----------|--------------------------|------------------|-------------------|------------------|------------------|
|                               |           | Treatment Groups (mg/kg) |                  |                   |                  |                  |
|                               | Phase Day | 0                        | 30               | 100               | 300              | 1000             |
| Creatine Kinase (IU/L)        | SD 14     | 188.6 ± 26.0 (5)         | 218.4 ± 40.4 (5) | 310.6 ± 138.2 (5) | 169.2 ± 14.7 (5) | 222.2 ± 48.8 (5) |
| Percent of Control            |           |                          | 115.8            | 164.7             | 89.7             | 117.8            |
| Sorbitol Dehydrogenase (IU/L) | SD 14     | 14.7 ± 2.5 (5)           | 17.3 ± 3.9 (5)   | 14.2 ± 2.4 (5)    | 12.6 ± 0.7 (5)   | 13.5 ± 1.5 (5)   |
| Percent of Control            |           |                          | 117.5            | 96.7              | 85.9             | 91.8             |
| Bile salt/acids (µmol/L)      | SD 14     | 22.0 ± 4.1 (5)           | 28.4 ± 3.1 (5)   | 5.6 ± 0.6 (5) *   | 17.8 ± 4.1 (5)   | 14.0 ± 3.0 (5)   |
| Percent of Control            |           |                          | 129.1            | 25.5              | 80.9             | 63.6             |

**Study Number:** C12005-01

**Test Type:** TOX

**Route:** Oral Gavage

**Species/Strain:** Rat/Harlan Sprague Dawley

**PA41: Clinical Chemistry Summary**

**Test Compound:** Octrizole

**CAS Number:** 3147-75-9

**Date Report Requested:** 04/08/2026

**Time Report Requested:** 15:47:33

**Lab:** Battelle

#### LEGEND

---

Values given as mean  $\pm$  SEM (N) with Percent of Control calculated by (dosed group mean / control group mean) x 100.

SD = Study Day

Statistical analysis was performed by Jonckheere (trend) and Shirley or Dunn (pairwise) tests.

Statistical significance for the control group indicates a significant trend test.

Statistical significance for a treatment group indicates a significant pairwise test compared to the vehicle control group.

\* Statistically significant at  $p \leq 0.05$

\*\* Statistically significant at  $p \leq 0.01$

SEM = Standard Error of the Mean

**\*\* END OF REPORT \*\***